These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12159894)

  • 41. Federal agency revises rule on financial disclosure by researchers.
    Maloney DM
    Hum Res Rep; 1999 Feb; 14(2):1-2. PubMed ID: 11657602
    [No Abstract]   [Full Text] [Related]  

  • 42. Drug makers are still giving gifts to doctors, F.D.A. officials tell senators.
    Harris G
    N Y Times Web; 2005 Mar; ():A15. PubMed ID: 15948332
    [No Abstract]   [Full Text] [Related]  

  • 43. The invisible influence of industry inducements.
    Rhodes R; Capozzi JD
    Am J Bioeth; 2003; 3(3):65-7. PubMed ID: 14594501
    [No Abstract]   [Full Text] [Related]  

  • 44. The physician and the pharmaceutical industry: both must keep the patient's interests at heart.
    Ravindran GD
    Issues Med Ethics; 1999; 7(1):21-2. PubMed ID: 16320467
    [No Abstract]   [Full Text] [Related]  

  • 45. [Physicians and the drug industry. "To be like that, you'd better be married."].
    Peiró S
    Rev Calid Asist; 2009 Apr; 24(2):47-50. PubMed ID: 19426926
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
    Jones TM
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-32. PubMed ID: 18345554
    [No Abstract]   [Full Text] [Related]  

  • 47. Drug industry is told to stop gifts to doctors.
    Pear R
    N Y Times Web; 2002 Oct; ():A1, A29. PubMed ID: 12474836
    [No Abstract]   [Full Text] [Related]  

  • 48. Both sides of pharmaceutical promotion.
    Crigger NJ; Bennison LW
    Adv Nurse Pract; 2007 Jan; 15(1):61-2, 64-5, 74. PubMed ID: 19998677
    [No Abstract]   [Full Text] [Related]  

  • 49. Tough-talking journal editor faces accusations of leniency.
    McNeil DG
    N Y Times Web; 2006 Aug; ():F1, F3. PubMed ID: 16906685
    [No Abstract]   [Full Text] [Related]  

  • 50. Sunshine laws and the pharmaceutical industry.
    Brennan TA; Mello MM
    JAMA; 2007 Mar; 297(11):1255-7. PubMed ID: 17374820
    [No Abstract]   [Full Text] [Related]  

  • 51. Pushing drugs to doctors.
    Consum Rep; 1992 Feb; 57(2):87-94. PubMed ID: 11651202
    [No Abstract]   [Full Text] [Related]  

  • 52. Pharmaceutical sales reps: value beyond samples.
    Flewell MN
    Adv Nurse Pract; 2006 Jul; 14(7):18. PubMed ID: 16977890
    [No Abstract]   [Full Text] [Related]  

  • 53. Relationships with the drug industry: More regulation, greater transparency.
    Krumholz HM; Ross JS
    BMJ; 2009 Feb; 338():b211. PubMed ID: 19193612
    [No Abstract]   [Full Text] [Related]  

  • 54. The pharmaceutical industry: friend or foe?
    Niebyl JR
    Am J Obstet Gynecol; 2008 Apr; 198(4):435-9. PubMed ID: 18395035
    [No Abstract]   [Full Text] [Related]  

  • 55. Show us the money: lessons in transparency from state pharmaceutical marketing disclosure laws.
    Chimonas S; Rozario NM; Rothman DJ
    Health Serv Res; 2010 Feb; 45(1):98-114. PubMed ID: 19840133
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Doctors, drug companies, and gifts.
    JAMA; 1990 Apr; 263(16):2177-9. PubMed ID: 2363745
    [No Abstract]   [Full Text] [Related]  

  • 57. Doctors object as drug makers learn who's prescribing what.
    Saul S
    N Y Times Web; 2006 May; ():A1, C4. PubMed ID: 16718959
    [No Abstract]   [Full Text] [Related]  

  • 58. It's time to shine the light on direct-to-consumer advertising.
    Mackey TK; Liang BA
    Ann Fam Med; 2015; 13(1):82-5. PubMed ID: 25583897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conflicts of interest between physicians and the pharmaceutical industry and special interest groups.
    Schetky DH
    Child Adolesc Psychiatr Clin N Am; 2008 Jan; 17(1):113-25, ix-x. PubMed ID: 18036482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. U.S. limits H.M.O.'s in linking bonuses to cost controls.
    Pear R
    N Y Times Web; 1996 Dec; ():A1, A24. PubMed ID: 11648055
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.